Acorn Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Acorn Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6M	Buy	+287,826	New	+$2.19M	0.46%	18

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acorn Capital Advisors's KPTI Position: Q1 2026 in Review

Acorn Capital Advisors opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 287,826 shares worth $1.6M. The stake represents 0.46% of the portfolio and ranks #18 among its holdings.

77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Acorn Capital Advisors held 287,826 shares of Karyopharm Therapeutics worth $1.6M as of Q1 2026.
Karyopharm Therapeutics was a new Acorn Capital Advisors position in Q1 2026.
Karyopharm Therapeutics made up 0.46% of Acorn Capital Advisors's portfolio in Q1 2026, its #18 holding.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.